Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Tr… (NCT05141513) | Clinical Trial Compass
RecruitingPhase 1
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
United States25 participantsStarted 2022-05-06
Plain-language summary
This study is designed to investigate the safety of intraoperative radiation therapy (IORT) in patients with localized pancreatic cancer undergoing surgical resection after neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \> 18 years old
✓. Resectable/BRPC/LAPC as defined by NCCN guidelines (Figure 1) as follows confirmed via CT, EUS, or other imaging modalities.
✓. ECOG performance status 0-2
✓. Subject or authorized representative, has been informed of the nature of the study and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) of the respective clinical site.
✓. Candidate for SBRT at JHU
✓. Upfront treatment with multi-agent chemotherapy